Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?

Published:2009 Issue:3-4 Volume:77 Page:217-223
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Hashimoto Kenji,Ueno Hideki,Ikeda Masafumi,Kojima Yasushi,Hagihara Atsushi,Kondo Shunsuke,Morizane Chigusa,Okusaka Takuji

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The relationship between LDH and GLIM criteria for cancer cachexia: Systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-07

2. Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma;Biomedicines;2024-01-19

3. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches;Environmental Research;2024-01

4. Nine-year survival of a 60-year-old woman with locally advanced pancreatic cancer under repeated open approach radiofrequency ablation: A case report;World Journal of Clinical Cases;2022-11-16

5. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review;Cancers;2022-05-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP